EASTHAMPTON Cancer Incidence by Sex, 1993 - 1997 Expected and Observed Case Counts, with Standardized Incidence Ratios

| | Exp | <u>Obs</u> | <u>SIR</u> | | Exp | <u>Obs</u> | <u>SIR</u> | |
|-----------------------|---------------|--------------|-----------------|-------------------------|-------|------------|------------|--|
| Bladder, Urinary | | | | Melanoma of Skin | | | | |
| Male | 10.33 | 12 | 116 | Male | 6.13 | 5 | 82 | |
| Female | 3.85 | 2 | NC* | Female | 4.79 | 4 | NC* | |
| Total | 14.18 | 14 | 99 | Total | 10.92 | 9 | 82 | |
| Brain and Othe | er Central No | ervous Syste | <u>em</u> | Multiple Myeloma | | | | |
| Male | 3.35 | 3 | NC* | Male | 1.91 | 3 | NC* | |
| Female | 2.86 | 4 | NC* | Female | 1.74 | 2 | NC* | |
| Total | 6.21 | 7 | 113 | Total | 3.66 | 5 | 137 | |
| Breast | | | | Non-Hodgkin's Lymphoma | | | | |
| Male | 0.66 | 1 | NC* | Male | 8.22 | 6 | 73 | |
| Female | 60.52 | 54 | 89 | Female | 7.18 | 5 | 70 | |
| Total | 61.18 | 55 | 90 | Total | 15.40 | 11 | 71 | |
| Cervix Uteri | | | | Oral Cavity and Pharynx | | | | |
| | | | | Male | 6.57 | 3 | NC* | |
| Female | 3.93 | 3 | NC* | Female | 3.17 | 3 | NC* | |
| | | | | Total | 9.75 | 6 | 62 | |
| Colon / Rectum | <u>1</u> | | | Ovary | | | | |
| Male | 26.05 | 28 | 107 | | | | | |
| Female | 24.93 | 19 | 76 | Female | 7.29 | 11 | 151 | |
| Total | 50.98 | 47 | 92 | | | | | |
| Esophagus | | | | Pancreas | | | | |
| Male | 3.65 | 2 | NC* | Male | 3.87 | 4 | NC* | |
| Female | 1.28 | 1 | NC* | Female | 4.09 | 6 | 147 | |
| Total | 4.93 | 3 | NC* | Total | 7.97 | 10 | 126 | |
| Hodgkin's Dise | <u>ease</u> | | Prostate | | | | | |
| Male | 1.67 | 2 | NC* | Male | 62.31 | 39 | 63 ~- | |
| Female | 1.28 | 1 | NC* | | | | | |
| Total | 2.95 | 3 | NC* | | | | | |
| Kidney and Re | nal Pelvis | | Stomach | | | | | |
| Male | 5.89 | 5 | 85 | Male | 4.42 | 5 | 113 | |
| Female | 3.52 | 4 | NC* | Female | 2.68 | 3 | NC* | |
| Total | 9.41 | 9 | 96 | Total | 7.10 | 8 | 113 | |
| <u>Larynx</u> | | | | Testis | | | | |
| Male | 3.53 | 4 | NC* | Male | 2.44 | 2 | NC* | |

| Female | 0.97 | 0 | NC* | | | | |
|-----------------------------------|-------|----|-------------------|--------------------------------------|--------|-----|-------|
| Total | 4.50 | 4 | NC* | | | | |
| Leukemia | | | | Thyroid | | | |
| Male | 4.42 | 7 | 158 | Male | 1.24 | 1 | NC* |
| Female | 3.31 | 2 | NC* | Female | 3.18 | 3 | NC* |
| Total | 7.73 | 9 | 116 | Total | 4.42 | 4 | NC* |
| Liver and Intrahepatic Bile Ducts | | | | Uteri, Corpus and Uterus, NOS | | | |
| Male | 2.03 | 2 | NC* | | | | |
| Female | 0.85 | 0 | NC* | Female | 11.61 | 8 | 69 |
| Total | 2.87 | 2 | NC* | | | | |
| Lung and Broa | nchus | | All Sites / Types | | | | |
| Male | 32.83 | 25 | 76 | Male | 205.83 | 169 | 82 ~- |
| Female | 24.68 | 26 | 105 | Female | 191.80 | 175 | 91 |
| Total | 57.51 | 51 | 89 | Total | 397.63 | 344 | 87 ~- |
| | | | | | | | |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels